Tumori最新文献

{"title":"Effect of body mass index on immune checkpoint inhibitor efficacy in patients with advanced cancer.","authors":"Gülin Alkan Şen, Nihan Şentürk Öztaş, Ezgi Değerli, Murad Guliyev, Hande Turna, Mustafa Özgüroğlu","doi":"10.1177/03008916241291989","DOIUrl":"10.1177/03008916241291989","url":null,"abstract":"<p><strong>Background: </strong>The need for predictive factors regarding the response to immune checkpoint inhibitors (ICIs) is increasing. Recent research indicates that an enhanced response to ICIs is associated with a higher body mass index (BMI). This study aims to evaluate the relationship between response to ICIs and BMI in solid tumors.</p><p><strong>Methods: </strong>We retrospectively analyzed patients with advanced cancer treated with ICIs at one academic center. We compared the treatment responses of patients classified as underweight/normal weight (BMI <25) and overweight/obese (BMI ⩾ 25) according to their BMI at the initiation of ICI treatment. After excluding underweight patients, we also compared the progression-free survival (PFS) and overall survival (OS) of normal-weight, overweight, and obese patients.</p><p><strong>Results: </strong>Overall, 113 patients were evaluated. Forty-seven (41.6%) patients had BMI <25 and 66 (58.4%) patients had a BMI ⩾ 25. In underweight/normal patients, median PFS was 7.7 months (95% CI: 4.7-10.6) while it was 8.0 months (95% CI: 4.1-11.9) in overweight/obese patients (HR 1.16, 95% CI: (0.76-1.75), p=0.477). In underweight/normal patients, the median OS was 21.7 months (95% CI: 11.6-31.7) compared to 18.7 months (95% CI: 12.7-24.6) in overweight/obese patients (HR 1.06, 95% CI: (0.69-1.64), p=0.774). The objective response rate (ORR) was 38.3% in underweight/normal patients and 34.8% in overweight/obese patients (p = 0.707). After excluding underweight patients, there were also no significant differences in PFS (p = 0.914), OS (p = 0.642), and ORR (p = 0.909) between patients of normal weight, overweight, and obesity.</p><p><strong>Conclusion: </strong>Our research found no correlation between BMI and response to ICIs. Additional prospective studies are necessary to assess the effect of BMI on the response to ICIs.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"KRAS inhibitors in drug resistance and potential for combination therapy.","authors":"Lala S Rathod, Nikhil S Sakle, Santosh N Mokale","doi":"10.1177/03008916241289206","DOIUrl":"10.1177/03008916241289206","url":null,"abstract":"<p><p>Kirsten Rat Sarcoma (KRAS) is a potent target for cancer therapy because it acts as a signaling hub, engaging in various signaling pathways and regulating a number of cellular functions like cell differentiation, proliferation, and survival. Recently, an emergency approval from the US-FDA has been issued for KRAS^G12C inhibitors (sotorasib and adagrasib) for metastatic lung cancer treatment. However, clinical studies on covalent KRAS^G12C inhibitors have rapidly confronted resistance in patients. Many methods are being assessed to overcome this resistance, along with various combinatorial clinical studies that are in process. Moreover, because KRAS^G12D and KRAS^G12V are more common than KRAS^G12C, focus must be placed on the therapeutic strategies for this type of patient, along with sustained efforts in research on these targets. In the present review, we try to focus on various strategies to overcome rapid resistance through the use of combinational treatments to improve the activity of KRAS^G12C inhibitors.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High throughput sequencing reveals alterations in B cell receptor repertoires associated with the progression of hepatic cirrhosis to hepatocellular carcinoma.","authors":"Yingying Zhao, Fengyan Wang, Xiaofei Lei, Ziqiang Li, Qiwei Cao, Runze Jiang, Changqing Xu, Kun Li","doi":"10.1177/03008916241290638","DOIUrl":"https://doi.org/10.1177/03008916241290638","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is developed as a consequence of chronic liver cirrhosis, and both diseases are difficult to diagnose and differentiate. Accurate noninvasive biomarkers for HCC and liver cirrhosis are urgently needed.</p><p><strong>Methods: </strong>Here we used high-throughput sequencing to characterize the B cell receptor (BCR) repertoires from 36 HCC tumor samples and 10 liver cirrhosis (LC) tissue biopsies to understand the immune alterations during hepatic carcinogenesis.</p><p><strong>Results: </strong>The principal components analysis (PCA) showed that the pattern of BCR in HCC was distinct from that in LC. As measured by Clonality and Shannon indexes, the diversity of BCR repertoire was significantly lower in HCC than in LC (P < 0.01).</p><p><strong>Conclusion: </strong>Our results corroborated that the BCR diversity and composition could be closely correlated with hepatic carcinogenesis. And BCR repertoire may be used to predict the progression of HCC and design targeting immunotherapy in the near future.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142558879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of anti-inflammatory molecules from food on organoids derived from adenomatous polyps of FAP subjects.","authors":"Oscar Illescas, Antonino Belfiore, Luca Varinelli, Davide Battistessa, Susanna Zanutto, Clorinda Brignola, Francesco Segrado, Irene Cafferati, Maria Teresa Ricci, Giovanna Sabella, Massimo Milione, Vito Ladisa, Stefano Signoroni, Marco Vitellaro, Patrizia Pasanisi, Manuela Gariboldi","doi":"10.1177/03008916241291301","DOIUrl":"https://doi.org/10.1177/03008916241291301","url":null,"abstract":"<p><strong>Introduction: </strong>Individuals with Familial Adenomatous Polyposis (FAP) or <i>APC</i>-associated polyposis, an autosomal dominant inherited condition, develop multiple adenomatous polyps and have an increased colorectal cancer (CRC) risk. A change in diet can help reduce cancer risk, and several dietary components have an antitumor effect. We aimed to evaluate the potential of the anti-inflammatory and anticancer substances quercetin (QER), epigallocatechin gallate (EGG) and fisetin (FIS) in decreasing the risk of CRC by reducing the growth of polyps in an organoid model.</p><p><strong>Methods: </strong>Patient-derived organoid (PDO) lines were generated from polyps obtained from patients with FAP undergoing prophylactic colectomy. PDOs were treated with QER, EGG, or FIS to determine their effect on cell growth. Changes in caspase 3/7 activity and expression of inflammation and apoptosis mediators were assessed by luminescent and colorimetric assays.</p><p><strong>Results: </strong>Three PDO lines with different inactivating pathogenic variants in the <i>APC</i> gene were developed using a combinatorial approach. FIS was the most active of the three substances tested, presenting the lowest IC50 in all PDO lines (range: 42.6-9.2 uM). The IC50 was defined as the concentration required to halve the number of cells after 72 hours. All molecules tested induced apoptosis through activation of caspases 3/7.</p><p><strong>Conclusions: </strong>QER, EGG, and FIS can be easily taken from foods or dietary supplements, show toxicity on PDOs derived from adenomatous polyps, while they are known to be harmless on normal cells. Diets enriched with these substances could be potential supplemental treatments to reduce the risk of CRC in individuals with FAP.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142508866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative chemo-CIRT in Re/BRe pancreatic cancer: Insights from a multicenter prospective phase II clinical study (NCT03822936).","authors":"Amelia Barcellini, Silvia Molinelli, Alessandro Vanoli, Viviana Vitolo, Piero Fossati, Alessandro Vai, Anna Pagani, Frediano Inzani, Mattia Pecorilla, Giovanni Butturini, Catherine Klersy, Lorenzo Preda, Angelica Facoetti, Francesca Valvo, Ester Orlandi","doi":"10.1177/03008916241291341","DOIUrl":"https://doi.org/10.1177/03008916241291341","url":null,"abstract":"<p><strong>Purpose: </strong>There is debate about the optimal management of borderline resectable (bRe) and resectable (Re) pancreatic ductal adenocarcinoma (PDAC). Both preclinical and clinical evidence showed that carbon ion radiotherapy (CIRT) produces superior control on radioresistant histologies compared to conventional photon beam radiotherapy (RT). However, so far there is a lack of data concerning the integration of CIRT in a multimodal approach with chemotherapy and surgery for bRe/Re.</p><p><strong>Methods: </strong>We recently presented the first analysis of a multicenter prospective phase II clinical study aimed at assessing the feasibility and effectiveness of a neoadjuvant chemotherapy + short course of CIRT followed by surgery and adjuvant chemotherapy in the management of bRe/Re PDAC. The study was terminated early due to low patient enrollment.Herein, we reported a post-hoc analysis focusing on toxicity, dosimetry and translational assessment.</p><p><strong>Results: </strong>In our experience, CIRT can be integrated into a multimodal treatment strategy for bRe/Re PDAC, alongside chemotherapy and surgery. A case of fatal liver failure occurring three months post-surgery has been documented, likely related to the combination approach. Although the treatment plans were satisfactory according to the Local Effect Model (LEM) model, recalculations using the modified Microdosimetric Kinetic Model (mMKM) revealed suboptimal target coverage. Additionally, we observed an increased expression of PD-L1 following CIRT.</p><p><strong>Conclusions: </strong>This multimodal approach was well tolerated; however, clinicians should carefully monitor for vascular disorders during follow-up and further investigate surgical techniques after CIRT. The increased PD-L1 expression supports the immunogenic effects of particle therapy and lays the groundwork for future studies. To enhance the therapeutic ratio of CIRT treatments, integrating dose-averaged LETd (LETd-based objectives into the plan optimization process should be considered.</p><p><strong>Trial registration number: </strong>ClinicalTrials.gov Identifier: NCT03822936.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142508868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Self-perceived attitudes of Italian oncology nurses towards clinical trial involvement: A cohort observational study.","authors":"Elsa Vitale, Roberto Lupo, Luana Conte, Rocco Mea, Ivan Rubbi, Serena Iacovelli, Giorgio De Nunzio, Raffaella Massafra","doi":"10.1177/03008916241290736","DOIUrl":"https://doi.org/10.1177/03008916241290736","url":null,"abstract":"<p><strong>Background: </strong>Literature is lacking when it comes to oncology nursing attitudes in clinical trial involvement.</p><p><strong>Objective: </strong>To assess how Italian oncology nurses perceived their attitudes in clinical trials involvement.</p><p><strong>Methods: </strong>An on-line cohort observational study was carried out. Data collected included: sex, years of work experience in oncology field and 10 items assessing participants' self-perceptions of their attitudes in clinical trials. Linear regression was used to assess associations between work experience and self-perceived preparedness.</p><p><strong>Results: </strong>A total of 338 Italian oncology nurses were enrolled. Most nurses declared not receiving any specific training in oncology clinical trials (23.1%). No significant associations were reported between self- perceived attitudes in clinical trial involvement in the oncology setting and both work experience and clinical trial involvement.</p><p><strong>Conclusions: </strong>Cancer centers are improving cancer nursing research in supplying clinical care. But very few centers are involved in training oncology nurses. This gap seems to be very deep in taking into consideration the oncology nursing research in clinical trials, too.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142508780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fat necrosis after accelerated partial breast irradiation or hypofractionated whole breast irradiation: A case-control study.","authors":"Riccardo Ray Colciago, Eliana La Rocca, Carlotta Giandini, Maria Grazia Carnevale, Giulia Valeria Bianchi, Ilaria Maugeri, Catherine Depretto, Silvia Meroni, Anna Cavallo, Emanuele Pignoli, Laura Lozza, Tiziana Rancati, Maria Carmen De Santis","doi":"10.1177/03008916241291305","DOIUrl":"https://doi.org/10.1177/03008916241291305","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to compare the incidence of fat necrosis after accelerated partial breast irradiation (APBI) vs hypofractionated whole breast irradiation (WBI) in patients with early-stage breast cancer.</p><p><strong>Materials and methods: </strong>Data from early-stage breast cancer patients who underwent breast-conserving surgery and adjuvant radiotherapy between 2009 and 2022 were retrospectively collected. Radiation therapy consisted of APBI of 30 Gy in 5 daily fractions (Fx) (delivered in one week, consecutively) to the tumour bed or WBI (42.4 Gy in 16 Fx). Reports on fat necrosis were extracted from yearly mammograms and breast ultrasound imaging. The primary endpoint was the incidence of radiologically detected fat necrosis.</p><p><strong>Results: </strong>A total of 536 patients were included among the APBI and WBI cohorts, with 268 and 268 patients respectively. The three-year Kaplan-Meier actuarial rate of fat necrosis was 32.8% (95% CI: 30.0% - 35.6%) for APBI and 22.3% (95% CI: 19.7% - 24.9%) for WBI patients. Univariate Kaplan-Meier survival analysis revealed a Hazard Ratio of 1.6 [95% CI: 1.1 - 2.2; p = 0.0055] for the fat necrosis rate within the APBI group compared to WBI. Multivariate Cox proportional hazard regression confirmed significant associations between fat necrosis and APBI (HR = 2.2 95% CI: 1.2 - 4.0; p = 0.01).</p><p><strong>Conclusions: </strong>The occurrence of radiologically diagnosed fat necrosis was higher in the APBI group compared to the WBI. Further investigations aiming to identify a lower-dose schedule with comparable efficacy to 30 Gy in 5 Fx but fewer toxicities, particularly for high-risk patients, are warranted.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142508867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>PALB2</i> analysis in the diagnostic process of breast cancer: An Italian monocentric experience.","authors":"Maria Grazia Tibiletti, Ileana Carnevali, Sofia Facchi, Laura Libera, Corrado Chiappa, Fausto Sessa, Stefano La Rosa, Francesca Rovera","doi":"10.1177/03008916241290738","DOIUrl":"https://doi.org/10.1177/03008916241290738","url":null,"abstract":"<p><strong>Background: </strong>The clinical utility of germline <i>BRCA1</i> and <i>BRCA2</i> testing is well established in patients with family history suggestive for hereditary breast and ovarian cancer syndrome. Recently, germline <i>PALB2</i> pathogenic variants were also associated with an increased risk of breast and other cancers and, in the Italian population, it has been described in few studies without a systematic germline analysis of <i>BRCA1</i>, <i>BRCA2</i> and <i>PALB2</i>.</p><p><strong>Objectives and methods: </strong>In this study, we described ASST Sette Laghi cancer genetic counselling services' experience in the analysis of 402 patients with suspected breast and ovarian cancer syndrome, by using <i>BRCA1</i>, <i>BRCA2</i> and <i>PALB2</i> germline genetic test.</p><p><strong>Results: </strong>The frequency of <i>PALB2</i> pathogenic variants was 1.2% compared to 3.5% and 3.2% for <i>BRCA1</i> and <i>BRCA2</i>, respectively, whereas class 3 variants were detected in 0.3% and 0.5% of the <i>BRCA1</i> and <i>BRCA2</i> investigated patients, respectively. <i>PALB2</i> pathogenic variants were identified in patients with a strong family history for breast cancer. Moreover, <i>PALB2</i> variants were significantly associated with a younger age of breast cancer onset (mean age, 40.25 years) compared to <i>wild-type</i> patients (mean age 51.2 years, p-value = 0.0331). Similar to <i>BRCA</i>-associated breast cancer, the majority of <i>PALB2</i> breast cancers were identified at an advanced clinical stage. Pedigree analysis revealed a family history of breast and ovarian cancer syndrome in all <i>PALB2</i> pathogenic variants carriers (early breast cancer onset, bilateral breast cancer and ovarian cancer).</p><p><strong>Conclusion: </strong>In conclusion, the germline analysis of <i>BRCA1, BRCA2</i> and <i>PALB2</i> should be included in breast cancer clinical practice as a not negligible number of <i>PALB2</i> carriers could be identified and referred to specific surveillance protocols.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142508865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proton therapy for pediatric malignancies: Indications and challenges focusing on the oncological landscape.","authors":"Sabina Vennarini, Francesca Colombo, Andrea R Filippi, Ester Orlandi","doi":"10.1177/03008916241287016","DOIUrl":"https://doi.org/10.1177/03008916241287016","url":null,"abstract":"<p><p>Advances in therapeutic techniques and multimodal approaches have significantly improved the success rates of treatment for pediatric malignancies, with cure rates now close to 80%. This has led to an increase in long-term survival, with 0.10-0.15% of the general population being survivors of childhood cancer. In Italy, cancer registry data suggest that 75% of treated children become long-term survivors. However, these survivors face significant risks of late adverse events, including chronic diseases and severe conditions, highlighting the need for specialized follow-up care.Radiotherapy, a cornerstone of pediatric cancer treatment, contributes to late toxicities due to the susceptibility of growing tissues. Proton therapy offers advantages in reducing treatment-related toxicity, reducing the risk of secondary cancers, and allowing dose escalation for radioresistant tumors. Comparative studies suggest that proton therapy is superior in sparing healthy tissues and reducing long-term toxicities.Despite these benefits, challenges such as the high cost, limited proton therapy centers, and the need for clinical trials hinder the widespread adoption of proton therapy. Efforts to centralize care in high-ranking centers and ensure equitable access to proton therapy are crucial. In Italy, pediatric solid tumors are now eligible for proton therapy under national health policies, ensuring free access for all children.Dedicated proton therapy centers must provide comprehensive care involving multidisciplinary teams and supportive environments for pediatric patients and their families. Addressing current limitations and enhancing care environments are essential for improving outcomes for pediatric oncology patients.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142475833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practices and views about palliative care at the end of life: A survey of oncologists from the Italian region of Liguria.","authors":"Irene Giannubilo, Linda Battistuzzi, Tommaso Ruelle, Francesca Benedetta Poggio, Giulia Buzzatti, Alessia D'Alonzo, Federica Della Rovere, Chiara Molinelli, Maria Grazia Razeti, Simone Nardin, Luca Arecco, Marta Perachino, Diletta Favero, Roberto Borea, Paolo Pronzato, Lucia Del Mastro, Stefania Vecchio, Claudia Bighin","doi":"10.1177/03008916241287616","DOIUrl":"https://doi.org/10.1177/03008916241287616","url":null,"abstract":"<p><strong>Introduction: </strong>We conducted an online survey to investigate oncologists' clinical practices and views on palliative care at the end of life in the Italian region of Liguria.</p><p><strong>Methods: </strong>The survey included 29 items divided into three sections: participant characteristics (n=6), hospital resources and practices (n=11), participant practices and views (n=12).</p><p><strong>Results: </strong>Twenty-one of the 41 medical oncologists invited completed the survey (51%). Although almost all reported the presence of palliative medicine physicians at their hospitals (90%), nearly half (48%) stated that palliative medicine physicians were not responsible for managing cancer patients at end of life, and 21% reported routine participation of palliative medicine physicians in multidisciplinary meetings. Thirty-eight percent of the respondents stated they never consulted psychologists regarding end of life patient care, and 43% reported they rarely did. Notably, a substantial proportion of participants stated that they administered active treatments to patients with six months life expectancy. Regarding integration between oncology and palliative medicine, an equal proportion felt it had been fully (48%) or partially achieved (48%) at their hospitals.</p><p><strong>Conclusions: </strong>Participants seemed fairly satisfied with the level of integration between oncology and palliative medicine at their hospitals, which contrasts with other findings regarding, for instance, the scant participation of palliative medicine physicians in multidisciplinary meetings. Exploring the impact of the novel regional clinical healthcare pathway for palliative care on practices at hospitals in Liguria will be crucial to ensure that cancer patients at end of life receive quality care.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142475832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}